On 31 October 2006, orphan designation (EU/3/06/411) was granted by the European Commission to Apogenix GmbH, Germany, for recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule for the prevention of graft versus host disease.
Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule
Prevention of graft-versus-host disease
|Orphan designation status||
|EU designation number||
|Date of designation||
|September 2023||The sponsor’s name was changed from Apogenix AG to Apogenix GmbH.|
|January 2018||The sponsorship was transferred to Apogenix AG - Germany.|
Documents related to this orphan designation evaluation
EU/3/06/411: Public summary of positive opinion for orphan designation of recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule for the prevention of gra... (PDF/113.5 KB)
First published: 02/04/2009
Last updated: 02/04/2009
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: